Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sintilimab · IBI-308

Monoclonal antibody · Inhibitor of Programmed cell death protein 1 (PDCD1) · developed by Innovent Biologics Co.

Phase 3 Most advanced trial
3 Registered trials

What is Sintilimab?

Sintilimab is a recombinant human monoclonal antibody that binds the PD-1 receptor on T cells and blocks its interaction with the ligands PD-L1 and PD-L2, restoring T-cell activation and anti-tumor immune responses. It is being studied in advanced endometrial cancer, advanced solid tumors and advanced renal cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IBI-308
Drug type
Monoclonal antibody
Targets
Programmed cell death protein 1 (PDCD1), Programmed cell death 1 ligand 1 (CD274) (binding partner it blocks), Programmed cell death 1 ligand 2 (PDCD1LG2) (binding partner it blocks)
Mechanism
Inhibitor of Programmed cell death protein 1 (PDCD1)
Pathways
PD-1 signaling, T-cell activation
Therapy area
Oncology
Developer
Innovent Biologics Co. Ltd.
In trials of
HCM
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
8FU7FQ8UPK

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06584032 Phase 3 Advanced Endometrial Cancer Recruiting HCM
NCT05522231 Phase 2/3 Advanced Renal Cell Carcinoma Completed HCM
NCT03903705 Phase 1/2 Advanced Solid Tumor Completed HCM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Endometrial CancerAdvanced Renal Cell CarcinomaAdvanced Solid Tumor

Other drugs acting on PDCD1

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.